How Reddit and Wall Street See Kenvue as Buyout Nears

By Trey Thoelcke Published Aug 7, 8:45AM EDT

Quick Read

Kenvue (KVUE) missed Q2 EPS by a penny and withheld guidance as its pending $49 billion Kimberly-Clark (KMB) buyout caps all price discovery.
KMB shares fell over 20% in the past year after a viral China misinformation campaign hit Huggies, directly shrinking the stock portion of Kenvue's payout.
An appeals court revived Tylenol autism lawsuits against Kenvue, a legal overhang Kimberly-Clark will inherit when the deal closes in Q4.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Kimberly-Clark didn't make the cut. Grab the names FREE today.

How Reddit and Wall Street See Kenvue as Buyout Nears — © 24/7 Wall St.

Shares of Kenvue (NYSE:KVUE | KVUE Price Prediction) closed at $19.18 on August 6, slipping 2.5% after the consumer health giant posted a rare earnings miss. The move barely registered on Reddit, where Kenvue’s proprietary sentiment score reads a neutral 42 on very thin volume. That’s a signal that retail chatter has essentially gone quiet while the pending Kimberly-Clark (NYSE:KMB) buyout caps the debate.

Kenvue’s Q2 2026 broke a four-quarter beat streak. Adjusted EPS of $0.31 missed the $0.32 consensus, and revenue of $3.955 billion came in light. Adjusted gross margin compressed 70 basis points to 60.2% on inflation, tariffs, and FX. Kenvue withheld guidance and skipped its traditional conference call due to the pending $48.7 billion cash-and-stock deal, structured as $3.50 cash plus 0.14625 Kimberly-Clark shares per KVUE share.

Reddit Goes Quiet on Kenvue as the Deal Pins the Price

Discussion volume is minimal. The most-upvoted recent thread on r/stocks was “Bloomberg Reports Appeals Court Revives Tylenol Autism Lawsuits Against Kenvue (NYSE: KVUE)” from user danieljapps, which drew just 22 upvotes and 4 comments. The post flags that the appeals court ruled the lower court “went too far” in excluding plaintiff expert testimony, reviving litigation that could produce thousands of additional claims.

The tone seems cautious, not bearish. The core reasons:

Kenvue trades a hair below the deal-implied value, leaving little room for standalone upside.
Analyst consensus is Hold, with a nearly $20 price target, comprising 12 Hold and two Buy ratings.
Revived Tylenol autism litigation and UK talc claims are unresolved legal overhangs that the merger will inherit.

Kimberly-Clark’s China Problem Complicates the Combined Thesis

Kimberly-Clark beat on Q2 earnings with adjusted EPS of $2.12, yet cut its 2026 guidance to a low-single-digit decline in adjusted EPS attributable to the company, citing a viral China misinformation campaign against Huggies. Kimberly-Clark shares are down more than 20% over the past year, dragging down the stock portion of Kenvue’s payout.

What to Watch on Kenvue Into Close

CEO Kirk Perry says the combination remains on track for the fourth quarter of this year, pending foreign regulatory sign-off. Until then, expect Kenvue to trade as a spread on Kimberly-Clark, not on Tylenol lawsuit headlines or margin results.

Contact [email protected] for any questions or corrections.

Follow 24/7 Wall St. on Google

About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.